What GLP-1 telehealth providers need to know about compounding and marketing rules
A compliance explainer covering 503A and 503B compounding, state prescribing rules and ad claims, citing FDA warning letters sent to 30 telehealth firms in March 2026.
Recap by typeshit. Full story at Medical Device News Magazine.